Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD

Status:
Unknown status

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

The primary objective of study is to evaluate the no of patients which maintain the Hb level between 9.0 ~ 12.0 g/dl during the evaluation period

Phase 4

Samsung Medical Center